Statin Muscle Symptoms CK Interpreter
Statin Muscle Symptoms CK Interpreter
Muscle aches on a statin? Enter the CK and your laboratory’s own upper reference limit, say whether there are symptoms, and see what the European Atherosclerosis Society consensus on statin-associated muscle symptoms advises: continue, continue with monitoring, stop and rechallenge, or stop and assess for rhabdomyolysis.
Statin and muscle symptoms: stop, continue or rechallenge?
CK ÷ laboratory ULN + symptoms → actionA 63-year-old man with previous myocardial infarction on atorvastatin 80 mg reports aching thighs. CK 1,450 U/L; his laboratory’s upper limit is 170 U/L. Creatinine unchanged, urine clear, no recent exercise.
CK as a multiple of the laboratory’s own limit
Up to 4 × ULN: symptoms decide · above 4 × ULN: continue with monitoring if symptomatic at high risk · above 10 × ULN: stop, unless a secondary cause is found · above 40 × ULN with renal impairment or myoglobinuria: rhabdomyolysis
- ULN
- the laboratory’s upper reference limit for CK. It differs by laboratory, sex and ancestry, so the page asks for it rather than assuming one
- above
- the consensus uses strict comparisons (above 4, above 10, above 40), so exactly 10 times the limit is in the 4 to 10 band
- secondary cause
- exercise, trauma, intramuscular injection, seizure or hypothyroidism. The stop rule at 10 times the limit applies when none is found
Worked example
A 63-year-old man with previous myocardial infarction on atorvastatin 80 mg reports aching thighs. CK 1,450 U/L; his laboratory's upper limit is 170 U/L. Creatinine unchanged, urine clear, no recent exercise.
CK multiple = 1,450 ÷ 170 = 8.5 × ULN
Not above 40 and no renal involvement → not rhabdomyolysis
Not above 10 → the stop rule does not apply
Above 4 with symptoms, at high cardiovascular risk → the consensus says the statin can be continued with CK monitoring, and stopped if the CK exceeds 10 × ULN
Had the same 1,450 U/L been read against a textbook ULN of 200, it would be 7.3 × ULN; against a ULN of 120, 12.1 — and the answer would have been stop. The laboratory's own limit matters
What the EAS consensus advises, by CK multiple
| CK | With muscle symptoms | Without symptoms |
|---|---|---|
| Up to 4 × ULN | Low risk: reassess the need for a statin. High risk: withdraw and rechallenge, switch statin, lowest dose, intermittent dosing, or non-statin therapy | Continue; routine CK monitoring is not recommended |
| Above 4, up to 10 × ULN | High risk: continue with CK monitoring; stop if above 10 × ULN. Lower risk: no separate rule — reassess need | Significance unclear; look for another cause |
| Above 10 × ULN | Stop if no secondary cause; rechallenge at a lower dose of an alternative statin once CK normalises | Stop if no secondary cause |
| Above 40 × ULN with renal impairment or myoglobinuria | Rhabdomyolysis: do not restart; assess renal damage | Same |
Why the CK is only half the answer
Muscle symptoms are the commonest reason people stop statins, and most of them happen with a normal or only slightly raised creatine kinase. The European Atherosclerosis Society’s 2015 consensus on statin-associated muscle symptoms, led by Stroes, is built on that observation: the CK separates the rare, serious muscle injury from the common, benign one, and the management of the common one is about keeping LDL lowering going rather than about the CK.
The consensus works in multiples of the upper limit of normal. Up to four times the limit, symptoms and cardiovascular risk decide: at low risk, reconsider whether a statin is needed; at high risk, find a regimen the patient tolerates, starting with a withdrawal and rechallenge to see whether the symptoms really follow the drug. Between four and ten times the limit, in a high-risk patient with symptoms, the consensus says the statin can be continued with CK monitoring — a point worth emphasising, because pages that tell the reader to stop at four times the limit are more cautious than the source. Above ten times the limit with no secondary cause, stop. Above forty times the limit with renal impairment or myoglobinuria is rhabdomyolysis, and the statin should not be restarted.
Everything depends on the upper limit being the right one. CK reference intervals differ between laboratories, are higher in men than women, and are substantially higher in people of Black African ancestry. A CK of 1,450 U/L is 8.5 times a limit of 170 and 12.1 times a limit of 120 — continue on one reading, stop on the other. This page therefore asks for the limit printed on the patient’s own report and works the multiple out from it. Convert a result in µkat/L with the creatine kinase unit converter first.
Look for a second explanation before blaming the statin. Strenuous exercise, trauma, injections and seizures raise CK for days; hypothyroidism raises it and also increases statin myopathy; and interacting drugs raise statin exposure. The consensus makes its stop rule at ten times the limit conditional on no such cause being found. If a statin cannot be re-established, the LDL goal remains, and the LDL target by risk category interpreter sets it.
Frequently asked questions
At what CK level should a statin be stopped?
On the EAS consensus, above 10 times the upper limit of normal when no secondary cause such as exercise is found. Above 40 times the limit with renal impairment or myoglobinuria is rhabdomyolysis, and the statin should not be restarted. Between 4 and 10 times the limit, a high-risk patient with symptoms can continue with CK monitoring.
My muscles ache on a statin but my CK is normal. What now?
That is the commonest situation. At low cardiovascular risk the consensus advises reassessing whether a statin is needed. At high risk it advises keeping LDL lowering going: a trial off the statin with rechallenge, a different statin, the lowest dose, intermittent dosing, or a non-statin drug.
Why does the page ask for my laboratory’s upper limit?
Because the guidance is written in multiples of it, and CK upper limits vary between laboratories, between men and women, and with ancestry. The same CK can be 8 times one laboratory’s limit and 12 times another’s, which crosses the stop threshold.
Should CK be checked routinely on a statin?
No. The EAS consensus does not recommend routine CK monitoring, and the significance of a raised CK without symptoms is unclear. Check it when there are muscle symptoms.
Related calculators
References
- Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy — European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J. 2015;36(17):1012–1022.
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–188.
- Mach F, et al. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025;46(42):4359–4378. doi:10.1093/eurheartj/ehaf190.
Medical Disclaimer: The tools and content provided here are for educational and reference purposes only. They are not intended to substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be based on the comprehensive assessment of a qualified healthcare professional.